Scientific exchange · Dr. Emiko Vogel

15 Sept 2026 · In person · Dr. Emiko Vogel, Charité Berlin · MSL James Whitfield · Vantrexa

ReviewedVeeva CRMENG-0048—

Capture insight from this engagement

Location: Charité Berlin
Therapeutic area: Oncology
Country: Germany
Stakeholder tier: Tier 3
Strategic objective: Not linked
Initiative: Not linked
MSL: JWJames WhitfieldSenior MSL, Oncology (US East)
Product: Vantrexa (vantrelimab)

Topics discussed

Duration of response
Comparator checkpoint monotherapy
Infusion-reaction management

Scientific content used

VOYAGE-1 pivotal data summary
PD-L1 testing pathway infographic

Questions raised

No questions recorded.

Notes

Scientific exchange with oncology pharmacist at Charité Berlin. Discussed duration of response, comparator checkpoint monotherapy, infusion-reaction management.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Invite to advisory board

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 2
Strategic relevance: 3
Depth of exchange: 3
Actionability: 3

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0048

Audit history (0)

All create, update and approval events for this record

No audit events in sample data